Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery Disease

Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery

Exclusive Rights to Treat PAD With Placental Cells in the U.S.

HAIFA, Israel, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that the company has completed a major step in its
intellectual property strategy: the United States Patent and Trademark Office
has granted the Company U.S. Patent 8,529,888. This patent, the 26^th issued
to the Company, covers methods for the treatment of peripheral artery disease
with placental-derived adherent stromal cells. The treatment for PAD is one of
Pluristem's primary drug development areas. Based on priority date, the
expected expiration date of this patent is at least until 2028.

"This patent is an important milestone in Pluristem's intellectual property
strategy and brings us closer to realizing our vision - to become a world
leader in developing and manufacturing cell therapy products," said Zami
Aberman, Chairman and CEO of Pluristem. "We believe it is a key asset and
significantly enhances our competitive position in cell therapy-based

About PAD

Peripheral artery disease (PAD) is a decrease in blood flow to the lower
extremities due primarily from cholesterol plaque blocking the arteries to
these limbs. The disease is frequently seen in patients with diabetes and can
result in lower extremity ulcers and amputations. Approximately 18 million
people in the in the U.S. suffer from PAD with the resultant economic burden
estimated to average approximately $200B annually. Current therapeutic
methodologies have proven ineffective for many patients with severe PAD and
has led to the medical community's call for the development of cell therapies,
such as Pluristem's PLX-PAD, as an alternative and potentially cost-effective

About Pluristem's Intellectual Property Approach

Pluristem's IP portfolio currently includes 26 issued patents and about 100
worldwide pending patent applications fully owned by the company. Pluristem
has developed a four-tier strategy to protect its IP. The base of this tier
includes the purchase of the core patent surrounding the company's 3D cell
expansion technology initially developed at the Weizmann Institute of Science
and the Technion-Israel Institute of Technology. Further patent applications
have been filed based on advances in the methods of the 3D expansion of
Adherent Stromal cells (ASC) that includes culture methods and conditions. The
second tier relates to the Company's filing of "composition-of-matter" patents
surrounding the unique PLX cells expanded by the Company's 3D expansion
technology based on the cell's source, function, phenotype or other
characteristics. The third tier is directed to the filing patent applications
surrounding unique instruments and devices invented by Pluristem that are used
during the culture of the cells and their eventual administration. The fourth
tier consists of the filing of "method of treatment" patents surrounding the
application of Pluristem's PLX cells for different indications.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we mention the expected
expiration date of the patent discussed above, when we discuss the potential
to become a leader in our industry and the potential of the patent to support
our competitive position, we are using forward-looking statements. These
forward-looking statements and their implications are based on the current
expectations of the management of Pluristem only, and are subject to a number
of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         Daya Lettvin
         Investor & Media Relations Director

Pluristem Therapeutics Inc. Logo
Press spacebar to pause and continue. Press esc to stop.